15 results
8-K
EX-99.3
PRAX
Praxis Precision Medicines Inc
9 May 22
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
4:04pm
EVALUABLE PARTICIPANTS1 (N=14) COMPLETED (N=11) Age, mean (range) 59 (26-76) 62 (43-76) Gender (Male/Female) (n, %) 11/3 (79%/21%) 8/3 (73%/27
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
17 Dec 21
Regulation FD Disclosure
4:40pm
(range) 68 (58-75) 59 (43-75) 62 (43-75) Disease Duration, mean (range) 42 (14-57) 32 (11-52) 36 (11-57) Gender (Male/Female) (n, %) 5 / 2 (71%/29
DRS/A
EX-10.15
PRAX
Praxis Precision Medicines Inc
28 Aug 20
Draft registration statement (amended)
12:00am
, wherever used, the singular includes the plural, the plural the singular, the use of any gender applies to all genders. The word “or” has the inclusive
DRS
EX-10.16
PRAX
Praxis Precision Medicines Inc
22 Jul 20
Draft registration statement
12:00am
used, the singular includes the plural, the plural the singular, the use of any gender applies to all genders. The word “or” has the inclusive meaning
S-1
EX-10.14
b1g0hl82ur9krfsnuppy
25 Sep 20
IPO registration
5:19pm
DRS
u74k8 yyl35b
22 Jul 20
Draft registration statement
12:00am
S-1/A
ntmqo8s4azd6
9 Oct 20
IPO registration (amended)
6:09am
424B4
2ojjw
16 Oct 20
Prospectus supplement with pricing info
4:02pm
DRS/A
jnd9ig0
28 Aug 20
Draft registration statement (amended)
12:00am
10-K
ic96 masfx01xe
17 Mar 21
Annual report
8:33am
S-1
v5zk2i76 bupdoy4t3o4
25 Sep 20
IPO registration
5:19pm
- Prev
- 1
- Next